Prof David Bowtell
Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology
551 Scholarly works
60 Projects
HIGHLIGHTS
2024
Journal article
BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance
DOI: 10.1186/s12943-024-02048-12022
Research grants (ARC, NHMRC, MRFF)
Driving Improvements in Ovarian Cancer Survival Through Molecular and Clinical Studies
2020
Research grants (ARC, NHMRC, MRFF)
Evaluation of Fibroblastic Activation Protein Inhibitors (FAPI) as a Novel Radiopharmaceutical Targeting Cancer-Associated Fibroblasts for the Diagnosis and Treatment of Patients With Cancer of Unknown Primary: The FAPI-CUP Trial
2018
Journal article
Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma
DOI: 10.1038/s41467-018-05564-z2017
Journal article
Secondary somatic mutations restoring RAD51C and RAD51D associated with acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma
DOI: 10.1158/2159-8290.CD-17-04192017
Research Grant
Acrf Tumour Heterogeneity Program
2016
Journal article
Pericytes promote malignant ovarian cancer progression in mice and predict poor prognosis in serous ovarian cancer patients
DOI: 10.1158/1078-0432.CCR-15-1931
RECENT SCHOLARLY WORKS
2026
Journal article
Clinicopathologic and molecular predictors of survival in BRCA-deficient tubo-ovarian high-grade serous carcinoma
DOI: 10.1038/s41467-026-71134-32026
Journal article
Using polygenic risk scores to refine risk and outcomes in high-grade serous ovarian cancer in Australia.
DOI: 10.1158/1055-9965.EPI-25-18822026
Journal article
16P Integrative proteogenomics reveals survival-linked co-expression modules and an HR activity signature in high-grade serous ovarian cancer
DOI: 10.1016/j.esmoop.2026.1080412026
Journal article
FAPI-CUP: A prospective cohort study of patients with cancer of unknown primary (CUP) to evaluate a novel radiotracer, fibroblast activated protein (FAPI), targeting cancer-associated fibroblasts for primary site detection.
DOI: 10.1200/jco.2026.44.16_suppl.30722026
Journal article
IGNITE-Cerala: A phase II signal-seeking trial of ceralasertib targeting recurrent high-grade serous ovarian cancer with cyclin E1 overexpression with and without gene amplification.
DOI: 10.1200/jco.2026.44.16_suppl.55872026
Journal article
Rethinking ovarian cancer III: the past decade and future directions
DOI: 10.1038/s41568-026-00916-02026
Journal article
Abstract 6261: Inflammation-related exposures and histotype- specific ovarian cancer risk in the Ovarian Cancer Association Consortium (OCAC).
DOI: 10.1158/1538-7445.am2026-62612026
Journal article
Real-world comparative outcomes of neoadjuvant chemotherapy with interval cytoreductive surgery versus primary cytoreductive surgery in epithelial ovarian cancer: insights from the australian ovarian cancer study (AOCS)
DOI: 10.1016/j.ijgc.2025.103076